Skip to main
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is showing strong financial performance with 1Q26 net revenue of €6.4M and a projected 1Q26 and 2Q26 net revenue of $6M and $7.5M respectively. The company is executing well in a noisy reimbursement environment, showing 15% y/y decrease in op ex, and expects to achieve breakeven at or below €150M in revenue. With positive data points and a growing salesforce, Nyxoah has the potential to become a high-growth asset, but may need to bolster its balance sheet.

Bears say

Nyxoah is a medical technology company focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea, with its lead solution being the Genio system. The company has shown strong revenue growth in Q1 2021, but its gross margin and operating expenses were below analyst estimates. The completion of the ACCCESS study in late June 2026/early July 2026 could be a key catalyst, but label expansion is not expected until early-2027. The company has been in operation since 2009.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.